Citadel Advisors
YTEN

Citadel Advisors’s Yield10 Bioscience, Inc. Common Stock YTEN Stock Holding History

Citadel Advisors’s Portfolio YTEN Stock Details YTEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Hold
0
– -$1K – 9175
2015
Q1 		– Hold
0
– – – 8462
2014
Q2 		– Hold
0
– -$1K – 8389
2014
Q1 		– Hold
0
– – – 7777
2013
Q4 		– Hold
0
– – – 6855

Other funds holding YTEN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GWM
Grand Wealth Management Grand Rapids, Michigan $212M AUM 18.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's YTEN Position: Q1 2024 in Review

Citadel Advisors sold out of Yield10 Bioscience, Inc. Common Stock (YTEN) in Q1 2024, closing a stake of 421 shares — an estimated $2.42K sold.

Citadel Advisors first reported a position in YTEN in Q1 2014 and held it in 12 quarters. The position peaked at $49K in Q1 2019. 19 funds tracked by Wall St. Rank hold YTEN as of Q1 2024.

  • Citadel Advisors reported no remaining Yield10 Bioscience, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 421 Yield10 Bioscience, Inc. Common Stock shares in Q1 2024, an estimated $2.42K.
  • Citadel Advisors first reported a position in Yield10 Bioscience, Inc. Common Stock in Q1 2014 and held it in 12 quarters.
  • Citadel Advisors's Yield10 Bioscience, Inc. Common Stock position peaked at $49K in Q1 2019.
  • 19 funds tracked by Wall St. Rank held Yield10 Bioscience, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.